istock-497807150_erhui1979-1

erhui1979 / iStockphoto.com

27 November 2018Biotechnology

New policies weakening IP innovation incentives: report

Despite the importance of IP rights to biotech and biopharma innovation, recent decisions and new policies are weakening and reducing the scope of IP-based incentives, according to a report.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

UPC deals further blow to Dexcom in glucose monitor dispute with Abbott